Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.
You may also be interested in...
The Alnylam Turnaround: What Changed Investors’ Minds?
Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.
Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.